In our previous study, CB1 blockade with both antagonists produced a marked decrease in serum cholesterol and triglycerides, serum insulin, body weight, serum uric acid and liver TNFα together with increased adiponectin levels in the same MetS rat model [28]. Here, CNR1 is linked to metabolic syndrome.